Therapeutic agent for influenza virus infection – Japan (Patent No. 5560472)
Patent Details
Country of RegistrationJapan
Patent No.No. 5560472Registration DateJune 20, 2014
Aureobasidium (black yeast) culture medium (hereafter referred to as “Aureo culture medium”) and influenza drugs (especially Tamiflu®) were tested to see if they were effective in combination.After infection with the influenza virus, the survival rate of mice was 50% when Tamiflu® alone was administered, but the survival rate was as high as 75% in the group that received Tamiflu® in combination with the Aureo culture medium. These results proved that the combination of the influenza treatment and the Aureo culture medium was effective in reducing the severity of the disease. Furthermore, it was confirmed that 75% of the group that was administered the combination of Aureo culture fluid and EF lactic acid bacteria survived in good health without any side effects.
This Japanese patent covers the use of Aureobasidium pullulans-derived β-glucan as a therapeutic agent for influenza virus infection, building on research demonstrating AP-glucan's antiviral immune properties.
AP β-glucan's antiviral efficacy against influenza is claimed through enhanced innate antiviral responses. The mechanism likely involves NK cell activation, IFN-γ induction, and macrophage-mediated antiviral activity — all established properties of AP-glucan. Patent protection reflects experimental evidence for antiviral clinical utility.
Antiviral therapeutic patents for AP-glucan represent a clinically significant application area. The potential for AP β-glucan to reduce influenza severity through enhanced innate immunity is particularly relevant in the context of respiratory infection preparedness.
Iwai A., Uchiyama H.. Therapeutic agent for influenza virus infection – Japan (Patent No. 5560472). Japanese Patent Office. 2023.
For scientific reference only. Not medical advice. Consult a qualified healthcare professional. See our Medical Disclaimer.